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A B S T R A C T   
We report a randomized study comparing fludarabine in combination with busulfan (FB) or thiotepa (FT), as con- ditioning regimen for 
hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis. The primary study endpoint was progression-free 
survival (PFS). 
Sixty patients were enrolled with a median age of 56 years and an intermediate-2  or  high-risk  score  in  65%,  according to the  Dynamic  
International  Prognostic  Staging  System  (DIPSS).  Donors  were  HLA-identical  sibling  (n = 25), matched unrelated (n = 25) or single allele 
mismatched unrelated (n = 10). With a median follow-up of 22 months (range, 1 to 68 months), outcomes at 2 years after HSCT in the FB arm 
versus the FT arm were as follows:     PFS, 43% versus 55% (P = .28); overall survival (OS), 54% versus 70% (P = .17); relapse/progression,  36% 
versus 24%  (P = .24); nonrelapse mortality (NRM), 21% in both arms (P = .99); and graft failure, 14% versus 10% (P = .96). A bet-   ter PFS was 
observed in patients with intermediate-1 DIPSS  score  (P = .03).  Both  neutrophil  engraftment  and  platelet engraftment were significantly 
influenced by previous splenectomy (hazard ratio  [HR],  2.28;  95%  confi-  dence  interval  [CI],  1.16  to  4.51;  P = .02)  and  splenomegaly  at  
transplantation  (HR,  0.51;  95%  CI,  0.27  to  0.94;   P = .03). In conclusion, the clinical outcome after HSCT was comparable when using either 
a busulfan or thiotepa  based conditioning regimen. 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Myelofibrosis (MF), including primary and post essential thrombocythemia and polycythemia vera, is a 
clonal myelo- proliferative disorder with a heterogeneous clinical course, associated with several clinical and 
biological prognostic fac- tors used to predict survival in several scoring systems [1-3]. These factors can identify 
patients with a favorable prognosis (median survival of 8 to 10 years) from those with a shorter life expectancy 
(median survival of 1 to 4 years). 
 
  
 
 
 
 
 
 
 
 
 
 
Allogeneic hematopoietic stem cell transplantation (HSCT) 
is the sole curative treatment for MF and is currently recom- 
mended for fit patients with intermediate 2 or high risk MF 
up to 70 years of age [4]. The indication to proceed to HSCT did 
not change for most patients after the discovery of the role of 
the V617F mutation of the JAK 2 gene in the pathogenesis of 
the disease and the positive effects of JAK1/2 inhibitor ruxoliti- 
nib [5-7] for alleviating MF symptoms and reducing spleno- 
megaly. However, the toxicity of HSCT remains a major reason 
for concern, and conventional myeloablative conditioning 
(MAC) regimens can be proposed for only a small subgroup of 
young patients. For this reason, they have been replaced by 
reduced intensity regimens (RIC) [8-11], which can expand 
transplantation eligibility to older patients [12,13]. Moreover, 
the optimal intensity of the conditioning regimen remains to 
be defined [4]. Randomized clinical trials to address this point 
have not been carried out because of the lack of a formally rec- 
ognized standard conditioning regimen. In addition, owing to 
the rarity of MF as an indication for HSCT, conducting large 
Phase III studies in a reasonable time period is challenging. 
Nonetheless, based on the results obtained in a prospective, 
multicenter study by the European Group for Blood and Mar- 
row (EBMT), a RIC regimen based on fludarabine and busulfan 
can currently be considered a reasonable comparator for any 
prospective study [14]. Thiotepa is an alkylating agent that has 
been introduced in the conditioning regimen for allogeneic 
transplantation for its double effect on stem cell depletion and 
immune suppression [15] even in the context of RIC programs 
applied to myeloid malignancies, including MF [16-18]. For 
these reasons, we decided to compare thiotepa + fludarabine 
with busulfan + fludarabine in a Phase II randomized study, 
with the aim of collecting prospective controlled data that 
could provide a basis for future phase III studies. 
 
METHODS 
Patient Population 
This study was a multicenter, randomized, Phase II trial carried out in 21 
hospital transplantation programs in Italy (Appendix 1), coordinated by the 
Gruppo Italiano per il Trapianto di Midollo Osseo e Terapia Cellulare (GITMO) 
network. Eligible patients were age 18 to 70 years, had a diagnosis of primary 
or secondary MF, and had at least 1 of the following unfavorable prognostic 
factors: hemoglobin <10 g/dL or leukocytes >25 109/L or >1% circulating 
blasts or constitutional symptoms, moreover, they had a Karnofsky Perfor- 
mance Status score c60, and a Hematopoietic Cell Transplantation-Specific 
Comorbidity Index (HCT-CI) score <5. Donor inclusion criteria were age 18 to 
65 years and an HLA-identical sibling donor or HLA-matched unrelated donor 
by high  resolution DNA-based HLA-A,   B,    C, -DRB1 typing or 1 alle-    
le mismatched (class I) unrelated donor (for recipients up to age 60 years). 
We conducted the study in accordance with the International Conference 
on Harmonization for Good Clinical Practice and the appropriate regulatory 
requirements. The study was approved by the ethic committees of the partici- 
pating centers. The trial protocol was in accordance with the Declaration of 
Helsinki and is registered at www.ClinicalTrials.gov (NCT01814475). 
 
Randomization 
Patients were assigned at random (1:1) using a stratified biased coin algo- 
rithm with a variable block size strategy to receive the thiotepa + fludarabine 
or busulfan + fludarabine conditioning regimen. Randomization was central- 
ized at the Fondazione Mario Negri Sud (Santa Maria Imbaro, Chieti, Italy) and 
was done via a dedicated web-based system with remote data entry. Patients 
were stratified by donor type (related versus unrelated donor). 
 
Study Procedures 
Patients could be treated before transplantation according to the local policy, 
including the administration of JAK1/2 inhibitors. Splenectomy before transplan- 
tation was considered in patients with massive splenomegaly ( 22 cm) [19] in 
the major diameter at ultrasound scan unresponsive to medical treatment. 
The conventional regimen was i.v. fludarabine 30 mg/m2 on day -8 to day 
-3; i.v. busulfan (Busilvex; Pierre Fabre Pharma, Toulouse, France) 0.8 mg/kg 
for 4 doses on days -5 and -4 and for 2 doses on day -3, (total dose, 8 mg/kg). 
The experimental arm received i.v. fludarabine 30 mg/m2 on day -8 to day -3 
and i.v. thiotepa (Tepadina; Adienne, Lugano, Switzerland) 6 mg/kg for 2 
doses on days -4 and -3. Allogeneic stem cell transplantation consisted of the 
reinfusion of 5 to 10 £ 106/kg CD34+ stem cells from sibling or unrelated 
donors. Peripheral blood (PB) was the preferred source of stem cells. Graft 
versus host disease (GVHD) prophylaxis consisted of cyclosporine and meth- 
otrexate on days +1, +3, and +6. Antithymocyte immunoglobulin (ATG; Gen- 
zyme, Cambridge, MA) 3.5 mg/kg, on days -3 and -2, was administered to 
recipients of unrelated donor grafts. No ATG was administered to recipients 
of matched sibling donor grafts. 
The main outcome data were collected and the main assessments of 
adverse events performed at day +30, day +100, day +180, 1 year, and 2 years 
after transplantation. At the same time points, the achievement of full donor 
chimerism (FDC) (defined as >95% of cells being of donor origin as evaluated 
by molecular analysis of short tandem repeats) was evaluated on bone mar- 
row cells and PB mononuclear cells. Acute GVHD was assessed weekly for the 
first 3 months after transplantation and graded according to the Glucksberg 
scale [20]. Chronic GVHD was assessed at each follow-up visit and classified 
as mild, moderate, or severe according to the National Institutes of Health cri- 
teria [21]. 
First-line treatment of grade II-IV acute GVHD was based on standard 2 mg/ 
kg 6-methylprednisolone for 5 days. In responsive patients, the dose was reduced 
by 25% every 5 to 7 days, whereas unresponsive patients received second-line 
treatment in accordance with the protocol at each center. 
 
Outcomes 
The primary study endpoint was progression free survival (PFS), 
assessed at 1 year after transplantation. PFS was defined as the time from the 
date of randomization to the date of the first documented disease progression 
or relapse (according to the criteria of International Working Group for Mye- 
lofibrosis Research and Treatment [IWG-MRT] [22]) or death due to any 
cause. Secondary endpoints for efficacy and safety were cumulative incidence 
of nonrelapse mortality (NRM), overall survival (OS), rate of clinical hemato- 
logic and histologic responses (according to IWG-MRT criteria), rate of molec- 
ular remissions in patients with a molecular marker, cumulative incidences of 
neutrophil and platelet engraftment, and cumulative incidences of acute and 
chronic GVHD. NRM was defined as death due to any other cause than pro- 
gression of malignancy after HSCT. 
Neutrophil engraftment was defined as the number of days after trans- 
plantation taken to achieve an absolute neutrophil count of at least 0 5 109 
cells/L and platelet engraftment was defined as the number of days to main- 
tain an untransfused platelet count of at least 20 109 cells/L. Primary graft 
failure was defined as the absence of donor cells in the bone marrow by day 
+30 after transplantation. Secondary graft failure or rejection was defined as 
the absence of donor cells in the bone marrow by day +60 after transplanta- 
tion, following an initial hematopoietic chimerism. Adverse events were 
graded based on the National Cancer Institute Common Terminology Criteria 
for Adverse Events version 3.0. 
 
Statistical Analysis 
Because the number of patients with MF referred for HSCT is very limited, 
we chose our sample size on the basis of feasibility. The GITMO registry 
allowed a predicting accrual of 20 patients per year, so we calculated a sam- 
ple size of 60 patients over a 3-year enrollment period. 
Baseline categorical characteristics were compared between the FT and 
FB arms using the chi-square or Fisher exact test. Continuous variables were 
compared with Mann-Whitney U test. PFS and OS were estimated using the 
Kaplan-Meier method, and the log-rank test was applied to test differences 
between arms. NRM and cumulative incidence of relapse were estimated 
using cumulative incidence function, considering relapse and death as a com- 
peting event, respectively, and the Fine and Gray nonparametric test was 
used to assess between-arm differences. The univariate analyses were per- 
formed by fitting Cox models, and hazard ratios (HRs) with 95% confidence 
intervals (CIs) were reported. Acute and chronic GVHD were considered 
time-dependent variables, and their unadjusted effects on survival outcomes 
were tested with the Mantel-Byar test. All analyses were done according to 
the intention-to-treat principle. All reported P values were 2 sided, and the 
conventional 5% significance level was fixed. The Data Safety Monitoring 
Board for unexpected trends closely monitored the number of treatment fail- 
ures and serious adverse events. All analyses were done with SAS version 9.4 
(SAS Institute, Cary, NC). 
 
RESULTS 
Patient Characteristics 
A total of 62 patients were enrolled between July 2011 and 
November 2015. Two patients had a leukemia transformation 
before conditioning and were excluded from the analysis. 
Thirty patients were randomized to the standard FB arm and 
30 were randomized to the experimental FT arm, constituting 
the intention-to treat population. Three patients did not 
  
 
 
 
 
 
Figure 1. Patients disposition chart. 
 
receive the allocated treatment because of medical decision 
(2 patients) or withdrawn of consent (1 patient), so the per- 
protocol population comprised 57 patients (Figure 1). Patient 
characteristics are summarized in Table 1. The main clinical 
features were balanced between the FT and FB arms. The only 
difference is that more patients with an HCT-CI score of c3 
were allocated to the FT arm than to the FB arm (P = .07). 
 
Donors and Stem Cell Grafts 
Donors were HLA matched (10/10 antigens) in all 25 sib- 
ling donor transplants and in 25 of 35 unrelated donor trans- 
plants. The remaining 10 unrelated donors were mismatched 
for 1 single allele in HLA class I. The data presented in Table 2 
indicate no significant differences in the distribution of the 
main characteristics of the donors between the 2 treatment 
arms. Of the 57 patients who proceeded to HSCT, 51 (89%) 
received a peripheral  blood  stem  cell  graft  (median  dose, 
6 £ 106/kg CD34+ cells), and only 6 patients received a bone 
marrow graft (median dose, 4.7 £ 106/kg CD34+ cells). 
Engraftment 
There was no difference in the cumulative incidence of neu- 
trophil engraftment at 30 days between the FB and FT arms 
(93% [95% CI, 80% to 99%] versus 89% [95% CI, 75% to 97%]; 
P = .93). However, the cumulative incidence of platelet engraft- 
ment at 30 days was significantly higher in the FB arm (82% 
[95% CI, 75% to 97%] versus 71% [95% CI, 54% to 86%]; P = .04] 
(Figure 2A and B). Donor type, stem cell source, and dose of 
CD34+ cell dose infused did not have a significant impact on 
neutrophil and platelet engraftment. However, hematopoietic 
recovery was significantly influenced by spleen size at trans- 
plantation; in fact, patients with splenomegaly before  HSCT 
had significantly slower neutrophil and platelet engraftment 
(HR, 0.51 [95% CI, 0.27 to 0.94], P = .03 versus HR, 0.41 [95%  CI, 
0.22 to 0.77], P = .005), whereas the patients who had under- 
gone previous splenectomy had significantly faster neutrophil 
and platelet recovery (HR, 2.28 [95% CI, 1.16 to 4.51], P = .02 
versus HR, 2.49 [95% CI, 1.26 to 4.92], P =.009) (Table 3). In 
patients with splenomegaly, the median times to  neutrophil 
and platelet engraftment were 19 and 20 days, respectively— 
significantly longer than those in patients who were splenec- 
tomized or without spleen enlargement before HSCT (16 and  
14 days, respectively; P < .0001). 
Graft failure was observed in 4 out of 28 (14%) transplanta- 
tions in the FB arm and in 3 out of 29 (10%) in the FT arm (P = .96). 
Primary graft failure occurred in 5 transplantations (3 after FB 
conditioning and 2 after FT conditioning), and secondary graft fail- 
ure was observed in 2 transplantations (1 in each arm). Out of the 
7 patients with overall graft failure, 5 had received a transplant 
from an unrelated donor (3 HLA-matched and 2 HLA 
mismatched donors), and 6 had received a PB stem cell graft. 
 
GVHD 
The cumulative incidence of grade II-IV acute GVHD was 
20% (95% CI, 11% to 31%) and of grade III-IV GVHD was 8% (95% 
CI, 3% to 17%). Skin was the most commonly involved organ (8 
out of 17 patients; 47%). The cumulative incidence of overall 
chronic GVHD at 18 months was 15% (95% CI, 7% to 26%), and 
that of moderate chronic GVHD was 8% (95% CI, 3% to 17%). No 
patient developed severe chronic GVHD. Conditioning type, 
patient age, disease risk, donor type, and stem cell source had 
no significant impact on the incidence of acute or  chronic  
GVHD incidence. 
 
NRM and Adverse Effects 
In the intention-to-treat analysis, the cumulative incidence 
of NRM was 21% in both the FB and FT arms at 2 years post- 
HSCT (HR, 0.88; 95% CI, 0.28 to 2.73) (Figure 3A). Six out of 30 
patients (20%) in the FB arm and 6 out 30 (20%) in the FT arm 
died from transplantation-related causes. Causes of death 
included infections (n = 6), GVHD (n = 2), encephalopathy 
(n = 2), severe renal insufficiency (n = 1), and poor marrow func- 
tion (n = 1) and were distributed equally between the 2 arms. 
The most common conditioning regimen-related toxic 
effects assessed within 30 days after transplantation are listed 
in Table 4. Fewer grade 3-4 adverse events were reported in 
the FB arm compared with the FT arm (6 versus 11). The most 
frequently reported grade 3-4 adverse events were infections 
in the FB arm (4 events; 66%) and gastrointestinal toxicities in 
the FT arm [5 events (46%)]. 
 
Outcomes 
At 1 year after HSCT, responses according to the IWT-MRT 
criteria were evaluable in 17 patients in the FB arm and in   
21 patients in the FT arm. The overall response rate was 12 
(75%) in the FB arm and 17 (81%) in the FT arm (P = .70). Spe- 
cifically, rates of complete response, partial response, clinical 
improvement, and stable disease were 41% (n = 10) versus 
48% (n = 10), 18% (n = 3) versus 5% (n = 1), 12% (n = 2) versus 
14% (n = 3), and 0 versus 14% (n = 3), respectively. Relapse or 
progressive disease occurred in 5 patients (29%) in the FB arm 
and in 4 patients (19%) in the FT arm. V617F JAK2 evaluation 
was available for 55 of the 60 patients (92%), including 37 
with mutation (Table 1). Of these patients, 16 could be ana- 
lyzed for measurable residual disease at 1 year after trans- 
plantation; 5 of 6 patients (83%) in the FB arm and 6 of 10 
patients (60%) in the FT arm reached a molecular negativity 
(P = .59). With a median follow-up of 22 months (range, 0 to 
68  months),  by   an   intention-to-treat   analysis,   the   PFS   at 
2 years was 43% (95% CI, 25% to 60%) in the FB arm versus 55% 
(95% CI, 35%-71%) in the FT arm (P = .28) (Figure 3B). The 
respective OS at 2 years in the 2 arms was 54% (95% CI, 34% to 
70%) versus 70% (95% CI, 50% to 83%) (P = .17) (Figure 3C). At 
2 years after randomization, the cumulative incidence of 
relapse and progression was 36% (95% CI, 18% to 53%) in  the 
FB arm and 24% (95% CI, 10% to 41%) in the FT arm (HR, 0.55; 
95% CI, 0.21 to 0.46; P = .24). The per-protocol analysis 
(Appendix 2) was in keeping with that described by the inten- 
tion-to-treat analysis reported above. 
In univariate analysis, we observed that patients with 
intermediate-2 or higher DIPSS risk at transplantation had a 
  
Table 1 
Patient Clinical and Laboratory Characteristics at Transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Karyotype 
 
 
 
Jak mutation 
 
 
 
 
 
 
 
 
 
Previous therapy, n (%) 
 
 
 
 
 
PV indicates polycythemia vera; ET, essential thrombocythemia. 
*DIPSS Plus score was calculated in 20 patients without considering karyotype, which was unavailable. 
 
 
significantly lower PFS at 2 years compared with patients 
with intermediate-1 DIPSS risk (38% versus 68%; P = .03), 
owing to  an  elevated  risk  of  relapse  (38%  versus  10%;  
P = .02). We did not find any other significant associations 
among PFS, OS, and NRM and the main patient and trans- 
plantation characteristics. Specifically, the 2-year NRM, PFS, 
and OS were 17%, 57%, and 71%, respectively, when HSCT 
was performed with a HLA-identical sibling donor graft, 
compared with 24%, 42%, and 56% when HSCT was 
performed with  an  unrelated donor  graft (P = .48,  .23, and 
.18,  respectively).  Moreover,  no  significant  difference   in 
 
transplantation outcomes between matched unrelated 
donors and mismatched unrelated donors was identified, 
and the development of acute and chronic GVHD had no sig- 
nificant influence on outcomes (Appendix 3). 
Seven patients (2 patients in the FB arm and 5 in the FT 
arm) received donor lymphocyte infusion at a  median  of 
155 days (range, 32 to 376 days) after HSCT because of mixed 
chimerism (in 6 patients) or relapse (in 1 patient). Two patients 
underwent a second HSCT, at 119 days and 458 days after the 
first transplantation, for graft failure in 1 patient and hemato- 
logic relapse in the other. 
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Table 2 
Donor Characteristics 
 
Characteristic  All (N = 60) FB Arm (N = 30) FT Arm (N = 30) P Value 
HLA matching      
 Sibling 25 (42) 13 (43) 12 (40) .37 
 Unrelated matched 25 (42) 14 (47) 11 (37)  
 Unrelated mismatched 10 (17) 3 (10) 7 (23)  
Age, yr, median (range)  35 (20-66) 37 (20-60) 34 (20-66) .82 
Sex matching, n (%)      
Male donor/male recipient 32 (53) 14 (47) 18 (60) .54 
Female donor/female recipient 5 (8) 4 (13) 1 (3)  
Male donor/female recipient 11 (18) 6 (20) 5 (17)  
Female donor/male recipient 12 (20) 6 (20) 6 (20)  
ABO matching      
Compatibility 34 (57) 18 (60) 16 (53) .94 
Major incompatibility 14 (23) 6 (17) 8 (23)  
Minor incompatibility 12 (20) 6 (20) 6 (20)  
CMV matching*      
CMV- donor/CMV- recipient 2 (3) 0 2 (7) .06 
CMV- donor/CMV+ recipient 23 (40) 8 (28) 15 (52)  
CMV+ donor/CMV- recipient 2 (3) 1 (3) 1 (3)  
CMV+ donor/CMV+ recipient 31 (52) 20 (69) 11 (38)  
CMV indicates cytomegalovirus. 
* Data are missing for 2 donor-recipient pairs. 
 
 
Figure 2.  Neutrophil (A) and platelet (B) engraftment. 
 
Chimerism Analysis 
There was no significant difference in the rate of FDC in PB 
at day +30 after HSCT between  the  2  treatment  arms  (62%  
[13 of 21] in the FB arm versus 86% [19 of 22] in the FT arm;       
P = .14). However, rate of FDC was significantly lower in the FB 
arm compared with the FT arm at day +100 (24% [5 of 21]  in  
the FB arm versus 68% [13 of 19] in the FT arm; P = .02), but the 
differences  were  cancelled  at  subsequent   time   points 
(Figure 4). Rates of FDC in PB were similar after HSCT with sib- 
ling donor and unrelated donor grafts (sibling transplants: 64% 
[9 of 14] at day +30 and 50% [9 of 18] at day +100; unrelated 
transplants: 79% [23 of 29] at day +30 and 41% [9 of 22] at day 
+100; P = .49 and .70, respectively]. 
 
DISCUSSION 
Only a few prospective trials and several retrospective 
studies have been conducted in patients with MF undergo- 
ing HSCT (Appendix 4). The first prospective study con- 
ducted within the EBMT showed a 1-year NRM of 16%, a 5- 
year disease-free-survival (DFS) of 51%, and a 5-year OS of 
67% after receipt of a fludarabine + busulfan (8 mg/kg i.v.) 
conditioning regimen [14]. The second Phase II prospective 
trial, supported by the International Myeloproliferative Dis- 
order Research Consortium (MDPC), used a fludarabine + 
melphalan preparative regimen and reported quite encour- 
aging clinical results after transplants from HLA-matched 
sibling donors (2-year NRM, 22%; 2-year OS, 75%), but an 
unexpectedly high NRM of 59%, linked in part to graft fail- 
ure, affected the outcome after transplantations from unre- 
lated donors (2-year OS, 36%) [23].  As  detailed in  Appendix 
4, more intensive fludarabine-based preparative regimens 
(including melphalan or 2 alkylating agents or 1 alkylating 
agent plus TBI) generally reported a higher rate of NRM and 
lower risk of relapse; on the other hand, less intensive con- 
ditioning regimens appeared to be safer, albeit associated  
with an increased risk of recurrence. Moreover, several ret- 
rospective comparisons of different RIC regimens failed to 
recognize the superiority of 1 preparative treatment over 
another in terms of OS and PFS [24-28]. In 2010, the GITMO 
designed the first prospective randomized study with the 
  
Table 3 
Univariate Analysis of Factors Influencing Neutrophil and Platelet Engraftment 
 
Variable  Neutrophil Engraftment, HR (95% CI) P Value Platelet Engraftment, HR (95% CI) P Value 
Treatment      
 FB 1.00  1.00  
 FT 0.98 (0.57-1.68) .93 0.57 (0.33-1.00) .04 
Splenomegaly  0.51 (0.27-0.94) .03 0.41 (0.22-0.77) .005 
Splenectomy  2.28 (1.16-4.51) .02 2.49 (1.26-4.92) .009 
Donor      
 Sibling 1.07 (0.49-2.32) .87 1.63 (0.73-3.61) .23 
 URD, identical 0.92 (0.42-2.02) .84 1.28 (0.58-2.84) .54 
 URD, mismatched 1.00  1.00  
Stem cell source      
 Bone marrow 1.15 (0.49-2.70) .76 1.40 (0.60-3.31) .44 
 PB 1.00  1.00  
Infused CD34+ cell dose, £ 106/kg 
<2 0.75 (0.18-3.18) .70 1.58 (0.38-6.64) .53 
2-5 0.72 (0.37-1.37) .32 0.58 (0.30-1.12) .10 
 >5 1.00  1.00  
 
 
URD indicates unrelated donor. 
 
aim of identifying the most suitable RIC regimen for HSCT 
from sibling donors and unrelated donors. The conventional 
arm was represented by a fludarabine + busulfan regimen, 
based on the results of the prospective EBMT study [14]. We 
chose thiotepa because of its excellent  antitumor  and  
immune suppressive activity when included in conditioning 
regimens     and     its     common     use     in     MF      within 
the GITMO study group [16,19]. This Phase II study did not 
have the statistical power to claim any superiority between 
the 2 arms; however, it could generate useful data for future 
Phase III trials. A “pick the winner” design that  has been 
used for quite some time could be similarly good, if not bet- 
ter, and should be considered for future trials testing differ- 
ent conditioning regimens in MF [29]. The patients and the 
donors recruited had clinical features comparable with those 
in the previous prospective trials. Indeed, in this study, the 
proportion of unrelated donors was 58%, compared with 68% 
in the EBMT trial and 51% in the MDPC trial. 
 
 
 
Figure 3. NRM by treatment (intention to treat) (A), PFS by treatment (intention to treat) (B), and OS by treatment (intention to treat) (C). 
  
 
 
 
Table 4 
Adverse Events in the First 30 Days Post-Transplantation 
 
 
Adverse Event FB Arm, n (%) FT Arm, n (%) 
 
 Grade I-II Grade III-IV Grade I-II Grade III-IV 
All adverse events 24 6 19 11 
Gastrointestinal toxicities 8 (33) 0 3 (16) 5 (46) 
Fever 3 (13)  4 (21) 1 (9) 
Infections 3 (13) 4 (66) 6 (32) 0 
Cardiac toxicity 0 1 (17) 0 0 
Hepatic toxicity 0 0 0 1 (9)* 
Respiratory toxicity 2 (8) 1 (17) 0 1 (9) 
Renal and urinary 2 (8) 0 3 (16) 0 
disorders 
Nervous system 
 
1 (4) 
 
0 
 
0 
 
1 (9) 
disorders 
Vascular disorders 
 
0 
 
0 
 
1 (5) 
 
2 (18) 
Metabolism disorders 1 (4) 0 2 (10) 0 
Eye disorders 1 (4) 0 0 0 
Musculoskeletal disorders 2 (8) 0 0 0 
Psychiatric disorders 1 (4) 0 0 0 
* Venous occlusive disease of the liver. 
 
Comparing the distribution of disease stages among recipi- 
ents is more difficult, given the different MF scoring systems 
applied in these 3 studies. It is likely that a proportion of 
patients with low stage disease enrolled in these trials would 
have not been considered suitable candidates for HSCT accord- 
ing to the present guidelines [4]. Moreover, the application of 
more recent and accurate scoring systems would change the 
disease stage distribution; in our study, the proportion of 
patients with intermediate 2 and high risk disease increased 
from 63% according to the DIPSS to 85% according to the DIPSS 
Plus, taking into account transfusion dependence and platelet 
count in all patients and cytogenetic abnormalities in patients 
with available karyotype data [30]. Mutational status analysis 
could further improve disease stratification; however, all 
3 prospective studies were designed before 2010 and limited 
their analysis to JAK2 V617F mutations [31] and MPL muta- 
tions [32]; thus, to date, the prognostic significance of driver 
and transforming mutations after HSCT have been evaluated 
only in retrospective studies [33,34]. 
HSCT recipients in the FT arm had slower platelet recovery 
and higher rates of severe extrahematologic toxicities, particu- 
larly in the gastrointestinal tract. However, the NRM rate was the 
same in the 2 arms. Our overall NRM of 21% at 2 years was similar 
to that reported in the EBMT study (16% at 1 year) and within the 
range of NRM rates reported in previous studies (Appendix 4); 
moreover, in the unrelated donor transplant recipients in our 
study, both conditioning regimens were apparently safer than 
the fludarabine + melphalan regimen of the MDPC trial. Nonethe- 
less, in most studies, transplants from unrelated donors exhibited 
a higher risk of toxicity and mortality; in some of these, the 
increased risk was limited to mismatched donor transplants [14], 
whereas in others it included even transplants from matched 
unrelated donors [12,16,23-26,31,35,36], in which a high risk of 
graft failure and related-mortality are reported [26]. In the pres- 
ent study, GVHD did not seem to contribute to NRM, given the 
very low GVHD rates in both arms. 
Our 15% cumulative incidence of overall chronic GVHD may 
be related to a still short patient follow-up and to the decreasing 
rates of FDC during post-HSCT follow-up. On the other hand, 
both graft failure and mixed chimerism were matter of concern 
in our study, even if our graft failure of 12% was in the range of 
that reported in previous trials [8,11-14,16,19,37] (Appendix 4). 
High rates of FDC were reported in the first studies using RIC 
regimens, particularly when chimerism was evaluated shortly 
after transplant, at the time of engraftment [38,39]. However, 
recent studies evaluating chimerism at different time points are 
concordant with our observation of an increased rate of mixed 
chimerism during follow-up, particularly after less intensive 
conditioning regimens (Appendix 4) [28,40]. Donor lymphocyte 
 
 
 
Figure 4. Chimerism evaluation in peripheral blood at days +30, +100, and +180, according to treatment arm. DC, donor chimerism. 
  
 
infusion to maintain or achieve FDC has been reported in several 
studies [14,38,39]. We found that graft failure occurred inde- 
pendent of donor type, stem cell source, and conditioning regi- 
men. Indeed, the burden of immune suppression in the 
conditioning regimen and the GVHD prophylaxis varied among 
the 3 prospective studies and could help explain the different 
clinical results. Either ATG or fludarabine was administered at 
lower doses in the MDPC study (120 mg/m2 fludarabine and 
4.5 mg/kg Thymoglobuline), which reported higher graft failure 
and NRM compared with the EBMT and GITMO studies (180 
mg/m2 fludarabine plus 60 mg/kg Fresenius or 7 mg/kg Thymo- 
globuline), respectively. For the future, alternative GVHD pro- 
phylaxis may be considered, as proposed by Bregante et al [37], 
who reported a possible beneficial effect on NRM associated 
with the substitution of ATG with post-transplantation cyclo- 
phosphamide. 
In our study, the kinetics of hematopoietic engraftment was 
significantly influenced by the spleen size at the time of HSCT, 
as reported previously [33-36]. Only 15% of our patients had a 
spleen larger than 22 cm, but we observed that even a moder- 
ate splenic enlargement had a negative impact on hematopoi- 
etic engraftment, although it did not significantly influence 
overall outcome. At present, the management of splenomegaly 
before HSCT should be reconsidered after the introduction of 
JAK1/2 inhibitors. In the present study, we cannot draw any 
conclusions in this regard, because only 7 patients were pre- 
treated with ruxolitinib. We also saw faster engraftment of 
splenectomized patients, and this may be an additional option 
for patients with splenomegaly. 
Therefore, NRM remains a significant unmet need for 
patients with MF. Today, it is likely that the improvement in 
this setting will be achieved not by a different conditioning 
regimen, but rather via a global treatment strategy in which 
patients are not referred to HSCT too late. As expected, our 
multivariate analysis found a significantly higher PFS in 
patients with intermediate-1 MF compared with those with 
more advanced stage MF, confirming a lower disease burden 
as a favorable prognostic factor, as was previously reported 
after MAC [9,10,12] and RIC [14] HSCT. Because a subgroup of 
DIPSS Plus intermediate-1 patients can be considered for HSCT 
if they have adverse features as per National Comprehensive 
Cancer Network recommendations [41,42], the 68% PFS at     
2 years found in our study should be taken into consideration, 
even if the plateau of the curve needs to be confirmed with a 
longer follow-up, and comparisons with nontransplantation 
treatments are warranted [43,44]. 
Relapse, the other major determinant of long-term outcome, 
was comparable in our 2 treatment  arms.  Moreover,  relapse  rate 
is similar to that previously reported after busulfan based RIC regi- 
mens [14,25], but higher than that observed after melphalan [25].   
As suggested by the transplant group in Genova, adding thiotepa 
to busulfan and fludarabine [32], with the aim of improving com- 
plete donor chimerism and reducing the risk of relapse, may rep- 
resent an option that deserves further clinical investigation. 
We must acknowledge some limits of the present study, 
which are linked predominantly to the rarity of MF as indica- 
tion for HSCT and the long time required to recruit patients. 
First, the lack of analysis of driver and transforming muta- 
tions before transplantation did not allow a full evaluation of 
current prognostic factors [45]. Second, the limited number of 
patients enrolled did not allow us to score primary and sec- 
ondary MF separately [46]. Finally, the study's phase II design, 
although randomized, does not allow us to draw firm conclu- 
sions, and the issue of the best conditioning regimen in MF 
remains open. 
In conclusion, this prospective and comparative study shows 
that both fludarabine + busulfan and fludarabine + thiotepa are 
reasonably safe and moderately effective preparative treat- 
ments before HSCT from HLA-identical sibling and unrelated 
donors. The substitution of busulfan with thiotepa provided 
comparable disease control to that of the conventional RIC regi- 
men. Spleen size significantly influenced hematopoietic engraft- 
ment, whereas disease stage was the sole independent 
predictor for PFS. Our study findings demonstrate the need to 
address some open problems, such as the prevention of graft 
failure and recurrence, in future studies. 
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